Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion
- 1 August 1997
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 30 (2), 343-349
- https://doi.org/10.1016/s0735-1097(97)00187-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary HypertensionCirculation, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous ProstacyclinAnnals of Internal Medicine, 1994
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)Annals of Internal Medicine, 1990
- The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary HypertensionAmerican Review of Respiratory Disease, 1989
- High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.Circulation, 1987
- Primary Pulmonary HypertensionChest, 1987
- Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.Circulation, 1984